R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r) header
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r) profile picture

Financial markets trader/investor πŸ“ˆ #vaccineinjured w/ #POTS which onset after my Pfizer Covid vaccine #NEISvoidπŸ¦“πŸ₯„

somewhere in the USA
Joined August 2020
Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)Photo by R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ (@teaze_r)
What many may fail to recognize as a harm of the campaign to discredit the #vaccineinjured is that it will make it even harder for us to get meaningful help, both medical and financial. You are not just hurting our feelings; you are threatening our survival. (1)
6
30
128
13,441
I fully agree with this. Those NIH trials were designed to fail. So either all these experts are stupid or it is intentional. So disgusting.
The Regeneron POTS trial shows why almost all Long COVID treatment trials fail: It's their design. This is why I'm so confident that the Tirzepatide and SGB trials will fail, and why I honestly don't believe they're being run with good intentions:
29
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Sigh. So frustrating. Makes me take a deep breath this morning and remember why our collaborative work matters. These study results indicate that "Gamunex-C, a form of intravenous immunoglobulin (IVIG) that contains antibodies to help the body protect itself against infection from various diseases, does not have a significant impact on symptoms of severe postural orthostatic tachycardia syndrome (POTS) following COVID-19, according to results from the clinical trial RECOVER-AUTONOMIC (IVIG)." This raises serious questions about clinical trial design. In an effort to move quickly and at scale, we continue to study broad groups of patients who share a diagnosis but may have very different underlying biological mechanisms. We cannot continue treating patients with complex chronic illnesses as a homogeneous group simply because they share a diagnosis. These conditions are biologically heterogeneous, and trials must reflect that. Every trial should incorporate a strategy for patient subtyping, even when validated biomarkers are not yet available. Otherwise, we risk missing meaningful treatment responses in specific patient populations and dismissing potentially effective therapies. So, what HAVE we learned? This study has uncovered important insights. And that matters. We cannot throw up our hands when we encounter obstacles or a tough headline. β†’ It's NOT that IVIG is ineffective for all patients. This trial does not establish that. It simply showed that IVIG did not demonstrate an overall benefit in the population studied, broadly defined by post-COVID POTS. β†’ A shared diagnosis does not necessarily mean shared underlying biology or a shared response to treatment. β†’ These critical questions remains: Are there biologically defined subgroups that could benefit from IVIG, how do we identify them and how must we design trials capable of studying them? We need to examine the results, understand what they tell us, identify what remains unanswered, and use that knowledge to design better studies. Every study gives us something to build on, including this one, despite its outcome. recovercovid.org/news/latest…
7
7
2
42
2,777
I am active in several POTS communities online and when I hear others talk about their illnesses, I become so aware about how different we all are. It is crazy they lump us together for studies.
Bin gespannt wie die Einschlusskriterien waren. Weil wenn nicht nach zumindest plausibler AutoimmunitΓ€t gescreent wurde, wΓ€re das Ergebnis wenig ΓΌberraschend. 1/3
33
If they don't carefully select the subset of patients most likely to benefit this is what happens. Phase 2 should be where we discover who that group is. Did they even design the trial so we could discover that? OMG.
I have told people this was going to happen for months.
1
2
145
Hmmm. Regeneron. I didn't even know they were trialing a drug for POTS
1
90
Bought the dip, sold the rip. It's too soon to invest in this market. It's a trader's market and likely has some more downside in the coming months.
1
36
Nailed it.
Replying to @Dcpcooks
Everyone knows you buy the CEO slept with CCP spy dip
33
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Another lovely review, so glad Ekin is happy with the service! She was my first client from her country too! If you want help understanding "gifts" chronic illness brings like ME, POTS, MCAS, hydration, blood sugar issues, etc, you can book here: lc-sc.co.uk/book-an-appointm…
8
21
482
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Great article primarily about @LBatemanMD's hard work spanning over decades, but also with @RobWust and the work of @VirusesImmunity and @PutrinoLab. archive.today/sVXML #pwme #myalgicE #millionsmissing #severeME #LongCovid
4
47
2
156
4,528
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Democratic socialists get the attention, but moderates made this week's Democratic majorities. They delivered lion's share of House flips and vastly outperformed Bernie Sanders' Senate candidates. That & more in today's newsletter: wsj.com/politics/elections/a…
31
178
24
532
31,656
Hinojosa is a pragmatist who just wants fairness for her constitutients and the market acted like she was the reincarnation of Chairman Mao.
Am I crazy to think that if Texas Gov.-elect Gina Hinojosa were against the data center buildout, she wouldn't be saying I DO NOT HATE DATA CENTERS? Tech companies just need to pay the vig to communities to build. That's not a big deal.
1
1
77
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
On days like today, diversification matters. Beer, whisky, vodka, wine and tequila have all helped me forget about my portfolio.
159
714
44
7,547
250,044
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Look, sometimes the Nasdaq has to go down 6% so that those of us who are diversified value investors can feel great about being down slightly less that day.
183
191
26
6,517
199,914
Look forward to reading this paper by Harriet.
Latest paper: Hypothesis: Myalgic Encephalomyelitis (ME) as a Mast Cell Activation Disorder (MCAD) preprints.org/manuscript/202… This is a long paper because I wanted to "set the scene" so to speak and also cover anticipated and valid critiques. A wee summary below 🧡
1
1
70
This is very important to me because I have been harmed by doctors who refuse to recognize this. First they harm you, then they dismiss you, then they harm you some more. From the abstract:
🚨 Our new paper on #EDS/HSD, #MCAS and #dysautonomia as risk factors for adverse events and complications: an invited paper. Thanks to my co-authors, Drs. @KSivakoti89360 and Larry Afrin, for their contribution. tandfonline.com/doi/full/10.…
2
76
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
When vaccine injury research becomes political, patients are too often lost in the conversation. In a new article published by Brownstone Journal, React19's Brianne Dressen discusses the NIH's newly announced research initiative, the political narratives surrounding it, and why the focus must remain on those who have spent years seeking answers. For the vaccine-injured community, this research represents an important opportunity, but an announcement alone is not enough. Patients deserve rigorous science, transparency, meaningful follow-through, and research that ultimately leads to better recognition and care. Read Brianne's full article: brownstone.org/articles/when…
5
29
3
77
3,354
R. Anne Teaze πŸ₯„πŸ¦“ πŸ•ŠοΈ retweeted
Spot on
Stocks need to fall enough to make bonds rise enough so that the fed won't hike so stocks can rally
4
4
80
6,263